Sunvozertinib: a Promising Oral EGFR Inhibitor Approved for NSCLC with EGFR Ex20ins Mutations.

Lung cancer continues to be a significant health burden in the United States, with 2025 estimates indicating approximately 226,650 new cases and 124,730 deaths. NSCLC is the predominant histological subtype of lung cancer, representing approximately 80% to 85% of all diagnosed cases. Within the NSCLC cohort, the EGFR represents the most commonly altered tumor-initiating mutation, exhibiting the highest prevalence among actionable molecular aberrations. Ex20ins in the EGFR gene represent the third most common type of EGFR mutation, observed in approximately 0.3% to 2.9% of all NSCLC cases and 2% to 5% of EGFR-mutant NSCLC subtypes. In July 2025, the US FDA granted accelerated approval for sunvozertinib, an oral and irreversible EGFR tyrosine kinase inhibitor, for the treatment of NSCLC patients who have mutations in the EGFR Ex20ins. Sunvozertinib received conditional approval in China for the second-line NSCLC with mutations in the EGFR Ex20ins, based on safety and efficacy data derived from a Phase II clinical study. Before the approval of sunvozertinib, treatment approaches for EGFR Ex20ins-mutant patients with NSCLC were limited and largely suboptimal. Conventional EGFR-TKIs exhibited minimal clinical efficacy, primarily due to intrinsic structural resistance mechanisms conferred by these specific mutations. This manuscript focuses on the clinical studies that supported the USFDA accelerated approval of sunvozertinib, along with its ongoing and upcoming clinical trials, preclinical research, and other pharmacological aspects.